Deletion of the NADPH-Cytochrome P450 Reductase Gene in Cardiomyocytes Does Not Protect Mice against Doxorubicin-Mediated Acute Cardiac Toxicity

Cheng Fang, Jun Gu, Fang Xie, Melissa Behr, Weizhu Yang, E. Dale Abel, and Xinxin Ding

Wadsworth Center, New York State Department of Health, and School of Public Health, State University of New York at Albany, Albany, New York (C.F., J.G., F.X., M.B., W.Y., X.D.); and Division of Endocrinology, Metabolism, and Diabetes and Program in Human Molecular Biology and Genetics, University of Utah School of Medicine, Salt Lake City, Utah (E.D.A.)

Received April 15, 2008; accepted May 5, 2008

ABSTRACT:

A genetic mouse model (designated cardiomyocyte-Cpr-null) with cardiomyocyte-specific deletion of the cytochrome P450 (P450) reductase (Cpr) gene was generated in this study. CPR protein levels, as well as the enzyme activity of P450s, were greatly reduced in heart microsomes from the null mice compared with wild-type mice, whereas CPR expression in other organs remained unchanged. Nonetheless, homozygous null mice were normal in appearance, gross anatomy, tissue morphology, and general cardiac functional parameters, and there was no indication of embryonic lethality or premature mortality in contrast to the recognized role of CPR in embryonic development. Thus, this new mouse model should be useful for determination of the in vivo roles of cardiomyocyte CPR and CPR-dependent enzymes, including microsomal P450s, not only in the metabolism and toxicity of numerous xenobiotic compounds but also in cardiac pathophysiology. As a first application, we studied the role of cardiomyocyte CPR and CPR-dependent enzymes in doxorubicin (Dox)-mediated acute cardiotoxicity. Wild-type and null mice were treated with a single i.p. dose of Dox at 5, 10, or 20 mg/kg. The Dox treatment caused apoptosis and vacuolization in cardiomyocytes at the dose of 20 mg/kg and a significant increase in the levels of serum creatine kinase at 10 and 20 mg/kg in both wild-type and null mice. However, there was no significant difference in the extent of Dox-induced cardiac injury between the two strains; this lack of difference suggests that cardiomyocyte CPR and CPR-dependent enzymes do not play critical roles in the acute cardiotoxicity induced by Dox.

Cytochrome P450 (P450) enzymes metabolize numerous exogenous and endogenous compounds. Multiple P450 enzymes are expressed in the heart, where they may participate in the metabolism of therapeutic agents and environmental toxicants (Wang et al., 2002; Williams et al., 2003), as well as endogenous arachidonic acid (AA) (Wu et al., 1996). Cardiac P450 enzymes are believed to play critical roles in cardiac ischemia-reperfusion injury through either increases in the production of free radicals or else alterations in the metabolism of AA (Granville et al., 2004; Nithipatikom et al., 2004; Seubert et al., 2004). However, the proposed in vivo functions of endogenous cardiac P450s, either in xenobiotic metabolism and/or toxicity or else in cardiac pathophysiology, remain largely unconfirmed.

The activity of microsomal P450 enzymes is dependent on the participation of NADPH-P450 reductase (CPR), which provides electrons needed for P450-catalyzed monooxygenase reactions, as well as for the reactions catalyzed by several other enzymes, including heme oxygenases (HOs), cytochrome b5, squalene monooxygenase, and fatty acid elongases (cf. Gu et al., 2003). Mice with germline inactivation of the Cpr gene die at the embryonic stage as a result of abnormal development of the brain, eye, heart, and limbs (Shen et al., 2002). Recently, transgenic mouse strains in which the Cpr gene was flanked by two loxp sites (designated Cprnull mouse) were generated (Wu et al., 2003); this genetic engineering permits tissue-specific Cpr knockout in postnatal mice.

To facilitate efforts to determine the biological functions of cardiac P450 enzymes in adults, as well as the roles of cardiac CPR and CPR-dependent enzymes in drug-mediated cardiotoxicity, we have now generated a cardiomyocyte-specific Cpr-null mouse model, designated the cardiomyocyte-Cpr-null mouse. This new mouse model was generated by cross-breeding the Cprnull mouse with a transgenic mouse (named αMHC-Cre) that affords cardiomyocyte-specific expression of the Cre recombinase (Cre) (Abel et al., 1999). In the αMHC-Cre mouse, the expression of Cre was driven by the promoter of the α-myosin heavy chain gene. The new cardiomyocyte-Cpr-null mouse was characterized for potential abnormality in appearance, gross anatomy, heart morphology, and heart weight; potential occurrence of embryonic lethality or premature mortality; potential changes in general cardiac function; and potential compensatory expression of microsomal P450s and HOs. As the first application of this new model, we studied the role of CPR in cardiac pathophysiology.

This study was supported in part by National Institutes of Health Grants ES07462 (to X.D.) and HL70070 (to E.D.A., who is an established investigator of the American Heart Association).

Article, publication date, and citation information can be found at http://dmd.aspetjournals.org. doi:10.1124/dmd.108.021881.

ABBREVIATIONS: P450, cytochrome P450; AA, arachidonic acid; CPR, cytochrome P450 reductase; HO, heme oxygenase; Cre, Cre recombinase; Dox, doxorubicin; H&E, hematoxylin and eosin; PBS, phosphate-buffered saline; DAPI, 4,6-diamidino-2-phenylindole; TUNEL, terminal deoxynucleotidyl transferase dUTP nick-end labeling; CK, creatine kinase.
mouse model, we further determined whether the null and wild-type mice differ in their sensitivities to toxic doses of doxorubicin (Dox), a widely used anticancer drug; our purpose was to assess whether target-tissue CPR/P450-mediated Dox metabolism plays an important role in Dox-induced acute cardiotoxicity.

The clinical use of Dox is often limited by the dose- and time-dependent Dox-mediated acute and chronic cardiotoxicity (Singal and Linskovic, 1998; Menna et al., 2008). Although the mechanisms of Dox-mediated cardiotoxicity are not fully understood, oxidative stress seems to play an important role, as indicated by the occurrence of cardiac lipid peroxidation (Myers et al., 1977), glutathione depletion (Doroshow et al., 1981), and decreases in glutathione peroxidase expression and activity (Li and Singal, 2000) in Dox-treated animals. Dox-induced oxidative stress and cardiotoxicity can be alleviated by pretreatment of animals with antioxidants, such as N-acetylcysteine and probucol (Doroshow et al., 1981; Li and Singal, 2000). Dox can undergo one-electron reduction by one of several enzymes, including the CPR; the reaction produces a semiquinone free radical, which can either directly attack cellular macromolecules or else indirectly (through reactions with oxygen and redox cycling) yield superoxide anion, hydrogen peroxide, and hydroxyl radicals, with consequent cellular damage to the cardiac tissue (Xu et al., 2005). Bioretransformation of Dox in humans involves primarily the formation of doxorubicinol in a reaction catalyzed by carbonyl reductase, although Dox can also be metabolized by CPR through reductive deoxyglucosylation to a nontoxic metabolite (Nitiu et al., 2000; Riddick et al., 2005). The critical role of carbonyl reductase in Dox-induced cardiotoxicity has been shown with transgenic and knockout mouse models (Forrest et al., 2000; Olson et al., 2003); nevertheless, the in vivo function of CPR and P450 in Dox-mediated cardiotoxicity remained to be shown. Our findings establish that cardiomyocyte CPR and CPR-dependent enzymes do not play critical roles in the acute cardiotoxicity induced by Dox.

Materials and Methods

Generation of the Cardiomyocyte-Cpr-Null Mice. Heterozygous aMHC-Cre mice on the FVB genetic background (Abel et al., 1999) were first crossed with Cprlox/lox mice on a mixed C57BL/6 and 129/Sv background (Wu et al., 2003); the resultant aMHC-Creα/β/Cprlox/lox progeny were crossed with Cprlox/lox mice again, yielding pups with one of four possible genotypes: aMHC-Creα/β/Cprlox/lox (null) and aMHC-Creα/β/Cpr-lox/lox (wild-type littermate), as well as aMHC-Creα/β/Cpr-lox/lo (hemizygous) and aMHC-Creα/β/Cpr-lox/lox (heterozygous) (neither of the latter two was used for this study). Cre and Cpr genotypes were determined by polymerase chain reaction analysis of tail DNA, as previously described (Wu et al., 2003). All the animal studies were approved by the Institutional Animal Care and Use Committee of the Wadsworth Center.

Immunoblot Assays. Protein samples were fractionated on 10% polyacrylamide gels and transferred to nitrocellulose membranes (Bio-Rad, Hercules, CA). For immunodetection, the following rabbit or goat antibodies were used, as well as aMHC-Creα/β/Cpr-lox/lo and aMHC-Creα/β/Cpr-lox/lox (neither of the latter two was used for this study). Cre and Cpr genotypes were determined by polymerase chain reaction analysis of tail DNA, as previously described (Wu et al., 2003). All the animal studies were approved by the Institutional Animal Care and Use Committee of the Wadsworth Center.

Measurement of Microsomal P450 Activity. P450-catalyzed dealkylation activity was measured for cardiac microsomes with a sensitive fluorescence-based method (Ekins et al., 1998). The substrate, 3-cyano-7-ethoxycoumarin (also cyano-7-hydroxycoumarin, or CEC), can be dealkylated by several P450 enzymes, including CYP1A1, CYP1A2, and CYP2B1. Tissue pieces were pipetted 5 to 10 times with a wide-opening plastic pipette, and they were then quickly transferred to a 15-ml tube containing 5 ml of a stopping buffer (perfusion buffer containing 10% calf serum and 12.5 μM CaCl2). Cells in the tissue pieces were dissociated by gentle pipetting; the resulting cell suspension was filtered through a metal sieve (300-μm mesh), and the cells were allowed to settle by gravity for 10 to 15 min. The supernatant was decanted, whereas the cell pellet was collected and stored at −80°C until use.

Isolation of Cardiomyocyte. Ventricular cardiomyocytes were isolated according to a previously reported method (Cheng et al., 2004). Briefly, adult mice were injected with heparin (100 U/mouse) 30 min before surgical operation. Mice were anesthetized with a mixture of ketamine (10 mg) and xylazine (0.7 mg). The heart was quickly removed, placed in ice-cold perfusion buffer (Cheng et al., 2004), and then cannulated to a 22-gauge needle with a blunt tip. Perfusion was started immediately at a constant flow rate (3 ml/min) with prewarmed perfusion buffer (37°C). After perfusion for 3 to 4 min, the perfusion buffer was replaced with prewarmed (37°C) digestion buffer, which consisted of the perfusion buffer containing 0.25 mg/ml Liberase Blendzyme I (Roche, Indianapolis, IN), 0.14 mg/ml trypsin (Invitrogen, Carlsbad, CA), and 12.5 μM CaCl2. After 10–12 min, the perfusion with digestion buffer was stopped. The heart was cut into pieces of −1 mm3 in size in a 60-mm cell culture dish. Tissue pieces were pipetted 5 to 10 times with a wide-opening plastic pipette, and they were then quickly transferred to a 15-ml tube containing 5 ml of a stopping buffer (perfusion buffer containing 10% calf serum and 12.5 μM CaCl2). Cells in the tissue pieces were dissociated by gentle pipetting; the resulting cell suspension was filtered through a metal sieve (300-μm mesh), and the cells were allowed to settle by gravity for 10 to 15 min. The supernatant was decanted, whereas the cell pellet was collected and stored at −80°C until use.
permanent, as indicated by the fact that a decreased CPR expression protein were not significantly changed in other organs examined, from wild-type, but not in those from the null, mice; however, the low isolated cell preparations indicated minimal contamination by cardiac cytotes, we compared CPR protein levels in isolated cardiomyocytes activity toward cytochrome cardiomyocytes but also in cardiac fibroblast and endothelial cells fact that CPR and/or P450 are known to be expressed not only in samples, respectively (Fig. 1B). The occurrence of significant levels mutation in the null mice were 70 and 50% in ventricular and atrial analysis indicated that the extents of decrease in CPR protein expression were decreased in both the ventricular and atrial samples from the null mice compared with age-matched wild-type controls. Densitometric were analyzed in duplicate. B, densitometric analysis of the CPR band detected in A. The data shown represent the ratios of the averaged band intensities for the null mice versus the intensity for the wild-type littersmates. C, immunoblot analysis of CPR protein were detected with a polyclonal anti-rat CPR antibody. Microsomes from the heart and other tissues were prepared according to previously described methods (Gu et al., 2003). Protein concentration was determined by the bicinchoninic acid assay (Pierce, Rockford, IL).

Results

Cardiomyocyte-Specific Cpr Deletion. Tissue-specific deletion of the Cpr gene in the cardiomyocyte-Cpr-null mouse was shown by immunoblot analysis of microsomal preparations from various tissues of adult null mice and their wild-type littermates. As shown in Fig. 1A, for 2- to 4-month-old male mice, microsomal CPR protein levels were decreased in both the ventricular and atrial samples from the null mice compared with age-matched wild-type controls. Densitometric analysis indicated that the extents of decrease in CPR protein expression in the null mice were 70 and 50% in ventricular and atrial samples, respectively (Fig. 1B). The occurrence of significant levels of residual CPR protein in the null mice was not unexpected, given the fact that CPR and/or P450 are known to be expressed not only in cardiomyocytes but also in cardiac fibroblast and endothelial cells (Brittebo, 1994; Borlak et al., 2003). In experiments not shown, CPR activity toward cytochrome c was detected in ventricular microsomes from wild-type, but not in those from the null, mice; however, the low overall rates detected did not permit an accurate determination of the extent of decrease in the null mice. In contrast, the levels of CPR protein were not significantly changed in other organs examined, including liver, lung, kidney, and brain (Fig. 1C).

As expected, deletion of the Cpr gene in the cardiomyocyte was permanent, as indicated by the fact that a decreased CPR expression was found for cardiac microsomal samples from 13-month-old null mice compared with age-matched wild-type littersmates (data not shown). To confirm the occurrence of Cpr deletion in cardiomyocytes, we compared CPR protein levels in isolated cardiomyocytes from adult null and wild-type mice. Microscopic inspection of the isolated cell preparations indicated minimal contamination by cardiac fibroblasts (data not shown). As shown in Fig. 1, A and B, the level of microsomal CPR protein in the isolated cardiomyocytes was ~85% lower in the null mice than that in wild-type littersmates; this extent of decrease in CPR expression, which may partly reflect the presence of contaminating CPR-expressing cardiac fibroblasts, is similar to the known extents (80–90%) of Cre-mediated gene recombination in cardiomyocytes of other αMHC-Cre+/− mice (Duan et al., 2005).

The cellular distribution of CPR expression in the hearts of the null and wild-type mice was analyzed by immunohistochemistry (Fig. 2). In the wild-type mice, CPR protein was detected in the cardiomyocytes, the cell type that makes up cardiac muscle fibers, and also in other cell types, including cardiac fibroblasts and endothelial cells. In the null mice, the intensity of immunoreactive signals in the cardiomyocytes was reduced to the level seen in the negative control section, whereas CPR staining in other cell types remained unchanged compared with the staining intensity in the wild-type mice (Fig. 2). These results further showed that cardiomyocyte-specific Cpr deletion was achieved in the cardiomyocyte-Cpr-null mice.
crossed heterozygotes indicated no sign of embryonic lethality (data not shown). An analysis of genotype distribution among pups resulting from inter-crossing of heterozygotes indicated no increase in embryonic lethality. These results indicated that the hearts of the null mice are functionally indistinguishable from the wild-type mice (Table 1). Hemodynamic parameters of the adult mice, including systolic blood pressure, diastolic blood pressure, and heart rate, did not show significant difference between the wild-type and the null mice (Table 1).

Impact of Cpr Deletion on Cardiac Microsomal P450 Activity. Cardiac microsomes prepared from pooled ventricles from five to seven adult wild-type or null mice were assayed for activity in the O-deethylation of 3-cyano-7-ethoxycoumarin. With the substrate at 9.3 μM, the initial rates of 3-cyano-7-hydroxycoumarin formation for the null mice (0.09 ± 0.06 pmol/min/mg protein; mean ± S.D., n = 4) were significantly lower (P < 0.05) than the rates found for the wild-type mice (0.16 ± 0.07 pmol/min/mg protein; n = 4), a result indicating decreases in cardiac microsomal P450 activity concomitant with decreases in the level of CPR protein.

Impact of Cpr Deletion on Cardiac P450 and HO Expression in the Null Mice. Given the previously reported compensatory gene expression changes in the liver of the liver-Cpr-null mice (Gu et al., 2003; Henderson et al., 2003), we performed immunoblot analysis to detect potential compensatory increases in the levels of CPR-dependent enzymes, including P450 and HO, in the hearts of the cardiomyocyte-Cpr-null mice. As shown in Fig. 3, small increases in the levels of CYP1A1/2 and HO-2 proteins, but no increases in the levels of CYP2C, CYP2J, and CYP3A proteins, were observed in ventricular microsomes from the null mice compared with the levels in the wild-type mice. Densitometric analysis (not shown) of the immunoblots revealed that the extent of increase was ∼40% for both CYP1A1/2 and HO-2. The cardiac microsomal levels of CYP2B and HO-1 proteins were near the detection limit for both mouse strains, thus making it difficult to compare the relative expression levels between the two groups. The expression of CYP2E1 and CYP4A was not detected in either type of microsomal sample (data not shown).

Impact of Cardiomyocyte Cpr Deletion on Dox-Induced Acute Cardiotoxicity. The extent of Dox-induced acute cardiotoxicity was determined by three different indices: serum levels of CK, numbers of apoptotic cells, and degrees of histological abnormality. The serum levels of CK activity were determined for adult, male wild-type and null mice at 4 days after treatment of the animals with a single i.p. injection of Dox (at 5, 10, or 20 mg/kg, respectively) or saline. Dox treatment caused a dose-dependent increase of the CK levels in both wild-type and null mice compared with saline-treated groups; however, there was no significant difference in the CK levels either between saline-treated wild-type and null mice or between Dox-treated wild-type and null mice at any of the tested dosages (Fig. 4); the latter result is indicative of similar extents of Dox-induced acute cardiotoxicity in the two mouse strains.

Apoptosis in the heart was analyzed by TUNEL assay in adult, male wild-type and null mice at 2 days after treatment with doxorubicin (at 20 mg/kg) or saline. An earlier time point (2-day), compared with the time point chosen for CK determination and histological analysis (4-day), was selected based on previous reports indicating that cardiomyocyte apoptosis is an early event after Dox treatment (Arora et al., 2000). The numbers of apoptotic cells per millimeter squared of tissue section in saline-treated wild-type and null groups were similar, at ∼1/mm² (Fig. 5). Dox treatment caused a 3-fold increase in apoptotic cells in both wild-type and null groups (P < 0.01, versus saline-treated wild-type and null groups, respectively). However, there was no significant difference between Dox-treated wild-type and null mice.

Histological analysis of H&E-stained heart sections from saline-treated mice indicated that the hearts of wild-type and null mice are indistinguishable (Fig. 6, A and B). At 4 days after Dox treatment, hearts from both wild-type and null mice showed widely scattered foci of myocardial degeneration, which were absent in saline-treated mice, were found in ventricular and atrial myocardium in the Dox-treated mice from both strains (Fig. 6). These results further indicate that the deletion of Cpr in the cardiomyocytes does not protect the hearts from Dox-induced acute toxicity.
In this study, we have generated and characterized a mouse model with cardiomyocyte-specific deletion of the Cpr gene. The cardiomyocyte-Cpr-null mouse joins a growing list of conditional knockout mouse models that target the Cpr gene; these models can have valuable research applications in drug metabolism and toxicology. For example, Cpr was deleted specifically in hepatocytes in liver-specific Cpr-null mouse models through the use of an albumin-Cre transgenic mouse. Studies using the liver-Cpr-null mice, in which the liver microsomal CPR levels were reduced by ~95% from wild-type levels, revealed significant roles of hepatic CPR-dependent enzymes not only in cholesterol biosynthesis but also in systemic xenobiotic disposition and hepatic chemical toxicity (Gu et al., 2003). In a more recent study, a lung-Cpr-null mouse model was generated, in which Cpr was specifically deleted in a large fraction of type II alveolar epithelial cells and Clara cells (Weng et al., 2007).

**Table 1**

<table>
<thead>
<tr>
<th>Parameters of cardiac function in cardiomyocyte-Cpr-null mice</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body Weight (g)</td>
</tr>
<tr>
<td>----------------------</td>
</tr>
<tr>
<td>Wild-type</td>
</tr>
<tr>
<td>Null</td>
</tr>
</tbody>
</table>

**Fig. 3.** The impact of cardiomyocyte-specific Cpr deletion on cardiac P450 and HO expression. Microsomes prepared from pooled ventricles from five adult male mice were analyzed for each strain. Samples were loaded in duplicate. Each lane contained 10 μg of protein. The antibodies used are described under Materials and Methods.

**Fig. 4.** Dox-induced increase in serum CK activity. Three-month-old male mice were given a single i.p. injection of Dox (at 5, 10, or 20 mg/kg; n = 5) or saline (n = 4). Four days after Dox treatment, serum samples were obtained, and CK activity was determined as described under Materials and Methods. The enzyme activity (rate of formation of NADPH) was expressed as units per liter, which was calculated as [changes in absorbance per minute] × 4180. *, P < 0.05; **, P < 0.01, compared with saline-treated mice of the same strain (Student’s t test).

**Fig. 5.** Dox-induced cardiac apoptosis. Three-month-old male mice were given a single i.p. injection of Dox (at 20 mg/kg; n = 5) or saline (n = 4). Two days after treatment, apoptotic cells were detected by TUNEL assay in paraffin-embedded heart sections as described under Materials and Methods. ***, P < 0.01, compared with saline-treated mice of the same strain (Student’s t test).

**Fig. 6.** Dox-induced cardiac pathologic changes. Hearts were obtained 4 days after Dox (at 20 mg/kg) or saline treatment. Coronal sections of the heart were stained with H&E. A, saline-treated wild-type mice; B, saline-treated null mice; C, Dox-treated wild-type mice; D, Dox-treated null mice. The results shown are typical of four mice examined in each group. Arrows indicate sites of myocardial degeneration; bar = 50 μm.

**Discussion**

In this study, we have generated and characterized a mouse model with cardiomyocyte-specific deletion of the Cpr gene. The cardiomyocyte-Cpr-null mouse joins a growing list of conditional knockout mouse models that target the Cpr gene; these models can have valuable research applications in drug metabolism and toxicology. For example, Cpr was deleted specifically in hepatocytes in liver-specific Cpr-null mouse models through the use of an albumin-Cre transgenic mouse. Studies using the liver-Cpr-null mice, in which the liver
bolic activation plays an essential role in the lung tumorigenicity of 4-(methyliminoamino)-1-(3-pyridyl)-1-butane, a tobacco-specific carcinogen.

In the present study, we find that cardiomyocyte CPR is dispensable for cardiac function in adult mice, given that the cardiac histology and hemodynamics seen in the cardiomyocyte-Cpr-null mice were normal. This result was in contrast to the documented critical function of CPR during embryonic development. Germline deletion of Cpr caused embryonic death in midgestation, accompanied by severe structural defects in multiple fetal organs, including the heart (Shen et al., 2002). In our cardiomyocyte-Cpr-null model, the expression of Cre, controlled by the promoter of aMiC, is expected to occur as early as E8.5, and Cre-mediated homologous recombination in the cardiomyocytes can take place at E11.5 (Gaussin et al., 2002). The functional impact of the Cpr deletion on embryonic metabolism of endogenous P450 substrates, such as retinoic acids, may not be significant until E13 or later, when sufficient amounts of the pre-existing CPR protein in targeted cardiac cells have been degraded. By then, the role of CPR and CPR-dependent enzymes in cells targeted for Cpr deletion may be no longer critical for development. Alternatively, the metabolic deficiency in the Cpr-null cells could be overcome by surrounding cells with normal CPR expression; for example, retinoic acids accumulated in the Cpr-null cells could be transported to neighboring Cpr<sup>+</sup> cells for P450-mediated degradation. Notably, no developmental or structural defect was found in the lungs of our recently reported lung-Cpr-null mouse model, in which Cre-mediated Cpr deletion was also expected to occur in mid to late gestation (Weng et al., 2007).

The cardiomyocyte-Cpr-null model can be used to determine the biological functions of cardiomyocyte microsomal P450 enzymes in the heart. Although the overall level of P450 expression in the heart is quite low compared with the level in the liver and other portal-of-entry organs, specific P450 enzymes, such as CYP2J2 and CYP2C, are relatively abundant in the cardiovascular system, where they are thought to regulate various biological and/or pathological processes through the metabolism of pertinent endogenous substrates (Wu et al., 1996; Enayetallah et al., 2004). For example, a number of P450 enzymes, including CYP2J2 and CYP2C2, can metabolize AA to epoxyeicosatrienoic acids and hydroxyeicosatetraenoic acids (Fleming, 2001). The epoxyeicosatrienoic acids could play a protective role by dilating coronary arteries during ischemia and reperfusion (Campbell and Harder, 1999) as shown by findings from a cardiomyocyte-specific CYP2J2-transgenic mouse, in which microsomal AA epoxygenase activity was 3-fold higher than in the wild-type mouse and in which postischemic recovery of the left ventricular function was significantly improved (Seubert et al., 2004). On the other hand, 20-hydroxyeicosatetraenoic acid seems to play a major role in exacerbating cardiac postischemic damage (Nithipatikom et al., 2004). Nonetheless, definitive evidence has yet to be obtained for a role of endogenous P450 enzymes of the cardiomyocyte, as opposed to enzymes of cardiac vascular tissues (Enayetallah et al., 2004; Delozier et al., 2007) or elsewhere, in the postischemic cardiac injury. This knowledge gap can now be filled at least partly through studies using the cardiomyocyte-Cpr-null mice. In this context, we recently described another transgenic mouse model, termed the Cpr<sup>low</sup> (or Cpr<sup>lowmo</sup>) mouse, in which the expression of CPR was greatly decreased (although not abolished) in all the organs and cell types examined (Wu et al., 2005). In the hearts of the Cpr<sup>low</sup> mice, CPR expression at 2 months of age was decreased by ~90% compared with wild-type C57BL/6 and 129/Sv mice. The combined use of the Cpr<sup>low</sup> and the cardiomyocyte-Cpr-null mouse models will likely be useful for distinguishing the relative roles of cardiomyocytes and the cardiac vascular system in postischemic reperfusion injury.

Findings of previous in vitro studies had suggested that CPR is involved in Dox-mediated cardiotoxicity through its catalysis of a one-electron reduction of Dox; the semiquinone radical formed in this process can induce increased oxidative stress through the generation of superoxide anion and then hydrogen peroxide and reactive hydroxyl radicals (Riddick et al., 2005; Xu et al., 2005). However, the results from the current in vivo study do not support the notion that CPR plays a major role in Dox-mediated acute cardiotoxicity. Besides CPR, there are several other enzymes, including flavin reductase, NADH dehydrogenase, and xanthine oxidase, that could catalyze the one-electron reduction of Dox (Doroshow, 1983). The activities of these other redox enzymes in the cardiac tissue appear to be sufficiently high for mediation of Dox-induced toxicity even in the absence of contributions from CPR. Notably, our finding is consistent with that of Ramji et al. (2003), who studied the role of CPR in Dox-induced toxicity in cultured cells. They showed that, although microsomal CPR activities in CPR-overexpressing human lymphoblastoid cells and human liver microsomes correlated well with the rates of Dox reduction, the susceptibility of human breast cancer cells to Dox-mediated cytotoxicity could not be enhanced through overexpression of CPR (Ramji et al., 2003). However, it remains to be determined whether CPR plays a major role in Dox-induced chronic cardiotoxicity when animals are treated continually with the drug at doses lower than those used in the present study; the various enzymes capable of forming the Dox semiquinone radical may differ in their enzyme kinetic parameters with respect to Dox or in their propensity to be inactivated by the oxidants produced in Dox-induced redox cycling.

It will also be interesting to determine whether the Cpr<sup>low</sup> mouse model is protected against Dox-induced acute and/or chronic cardiotoxicity, given the potentially important role of CPR in the cardiovascular system. In the Cpr<sup>low</sup> mouse, the contribution of CPR to Dox-mediated toxicity would be substantially decreased in both cardiac muscles and cardiac vasculature. In that regard, although CPR expression is also decreased in the liver and elsewhere in the Cpr<sup>low</sup> mice, systemic Dox clearance is unlikely to differ between the Cpr<sup>low</sup> mice and wild-type mice. This assumption is supported by findings of a recent study using a liver-specific Cpr<sup>null</sup> mouse model; there, hepatic CPR/P450 did not play a critical role in Dox clearance (Henderson et al., 2006).

In summary, we have generated and characterized a transgenic mouse model with cardiomyocyte-specific Cpr deletion. The null mouse exhibits normal tissue morphology and cardiac function. An initial application of this mouse model led to the finding that cardiomyocyte CPR and CPR-dependent enzymes do not play a critical role in the acute cardiotoxicity induced by Dox in vivo. This new knockout mouse model will be valuable for exploring potential functions of cardiomyocyte P450 enzymes in various physiological and pathological processes, such as postischemic reperfusion injury and xenobiotic-induced cardiotoxicity.

Acknowledgments. We thank the Pathology Laboratory, as well as the Biochemistry and Molecular Genetics Core Facilities, of the Wadsworth Center for the use of their services. We also thank Dr. Adriana Verschoor for reading the manuscript.

References


